ANI Pharma (ANIP) Tops Q1 EPS by 12c, Offers FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance
May 5, 2016 8:01 AM EDTBAUDETTE, Minn., May 5, 2016 /PRNewswire/ --Â ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2016, and reaffirmed its financial guidance for 2016 as updated on April 4, 2016. The Company will host its earnings conference call this morning, May 5, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 93601942.
Arthur S. Przybyl, President and CEO, stated,
"ANI had a strong first quarter. Thus far in 2016, we have closed three acquisitions... More
